Hormonal
Tirzepatide use in non-diabetic obese patients can induce severe ketoacidosis, primarily through starvation ketosis driven by gastrointestinal side effects and reduced caloric intake, rather than diabetic mechanisms.
If you are using tirzepatide for weight loss, do not buy it over the counter without medical oversight. Be aware that severe nausea, vomiting, or diarrhea combined with low food intake can lead to dangerous acid buildup (ketoacidosis), even if you do not have diabetes. Seek immediate medical attention if you experience abdominal pain, vomiting, and rapid breathing.
We report the first case of ketoacidosis after the use of tirzepatide in an obese non-diabetic patient, secondary to the possibility of starvation ketoacidosis and insulin resistance.
Why this rating
Based on a single case report with Naranjo score of 6 (probable), lacking controlled trial data for this specific adverse event in non-diabetics.
Source
Tirzepatide-induced ketoacidosis in non-diabetic patients
Pathan Mohamad Rafe Iqbal et al. · European Journal of Case Reports in Internal Medicine · 2024
DOI 10.12890/2024_004357
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →